

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0154US1	Application No. 10/560,098
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1643
(37 CFR §1.98(b))			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/LB/	25	JP11-500916	01/26/1999	Japan			Abstract only	
	26	JP 2002-543822	12/24/2002	Japan				
	27	JP2004-086682	03/18/2004	Japan			Abstract only	
	28	JP 2003-515323	05/07/2003	Japan				
	29	WO 94/05690	03/17/1994	WIPO				
	30	WO 96/27011	09/06/1996	WIPO				
	31	WO 97/10354	03/20/1997	WIPO			English abstract	
	32	WO 00/069462	11/23/2000	WIPO				
	33	WO 01/036486	05/25/2001	WIPO				
	34	WO 2004/019966	03/11/2004	WIPO			English abstract	
	35	WO 04/111233	12/23/2004	WIPO			English abstract	
	36	WO 05/056604	06/23/2005	WIPO			English abstract	
	37	WO 2005/107784	11/17/2005	WIPO			English abstract	

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document				
/LB/	38	ARNDT et al., "Generation of a highly stable, internalizing anti-DC22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma," <i>Int. J. Cancer</i> , 107(5):822-829 (2003)				
	39	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> , 247:1306-1310 (1990)				
	40	CLACKSON et al., "Making antibody fragments using phage display libraries," <i>Nature</i> , 352:624-628 (1991)				
	41	COCHLOVIUS et al., "Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells", <i>The Journal of Immunology</i> 165:888-895 (2000)				
	42	DEJONGE et al., "In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-DC3 x anti-idiotype) induces long term survival of the murine BCL1 lymphoma model," <i>J. Immunol.</i> , 161(3):1454-1461 (1998)				
	43	DEPLANCO et al., "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," <i>Protein Engineering</i> , 7(8):1027-1033 (1994)				
	44	EIJINK et al., "Rational engineering of enzyme stability," <i>Journal of Biotechnology</i> , 113:105-120 (2004)				

Examiner Signature	/Lynn Bristol/	Date Considered	08/09/2009
--------------------	----------------	-----------------	------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.